CN
EN

CN
EN

Media

Dec 17, 2023

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM

The study by YolTech is a single-arm, open-label, dose-escalation clinical trial

Share

LATESTNEWS

CDE Clears IND Application for Therapeutic Candidate Targeting ATTR

Mar 18, 2024
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA

Mar 04, 2024
Investing in the Next Frontier of Healthcare: Navigating Opportunities in In Vivo Gene Editing Technologies

Feb 15, 2024